alexsl
MoonLake Immunotherapeutics (MLTX) traded lower on Thursday after Goldman Sachs downgraded the Swiss biotech to Sell from Neutral, citing concerns over the approvability of its lead asset, sonelokimab, for hidradenitis suppurativa, a skin condition.
While the company’s outlook has improved